Related Experiment Videos
A therapeutic role for BLyS antagonists.
1Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles 90033, USA. stohl@usc.edu
Lupus
|July 3, 2004
Summary
B lymphocyte stimulator (BLyS) is crucial for B cell survival. Targeting BLyS may treat systemic lupus erythematosus (SLE) by reducing disease activity and improving survival in patients.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- B lymphocyte stimulator (BLyS) is essential for B cell survival.
- BLyS overexpression is implicated in the pathogenesis of systemic lupus erythematosus (SLE).
- BLyS antagonists have shown therapeutic potential in preclinical SLE models.
Purpose of the Study:
- To evaluate the role of BLyS in SLE pathogenesis.
- To assess the safety and efficacy of a BLyS antagonist in human SLE patients.
Main Methods:
- Studies in mouse models of SLE.
- Phase I clinical trial in human SLE patients.
Main Results:
- BLyS overexpression contributes to SLE-like disease in mice.
- BLyS antagonists ameliorate disease progression and enhance survival in SLE mice.
- A BLyS antagonist demonstrated biological activity and safety in a phase I human trial.
Conclusions:
- BLyS is a significant therapeutic target for SLE.
- Targeting BLyS offers a promising strategy for SLE treatment.